ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
12/24
06:32 pm
arqt
Neutral
Is Suvretta's Stake Cut and FDA's Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? [Yahoo! Finance]
12/23
12:57 pm
arqt
Low
Arcutis Stock Is Up 100% in a Year but Here's Why One Fund Still Sold 1 Million Shares [Yahoo! Finance]
12/14
03:02 pm
arqt
Low
This Biotech Stock Could Cure Your Portfolio's Pain [Yahoo! Finance]
12/14
12:17 pm
arqt
Low
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals [Yahoo! Finance]
12/14
01:26 am
arqt
Low
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at Wall S
10/28/2025
08:30 am
ARQT
18.3%
BEAT
8/6/2025
04:00 pm
ARQT
-8.1%
BEAT
5/6/2025
04:00 pm
ARQT
-4.3%
BEAT
2/25/2025
04:00 pm
ARQT
8.4%
BEAT
11/28
10:06 am
Maintains
Outperform
Outperform
Mizuho
Low
-1.1%
11/28
10:06 am
Maintains
Outperform
Outperform
Mizuho
Low
-1.1%
10/30
11:19 am
Maintains
Neutral
Neutral
Goldman Sachs
Low
-2.2%
10/30
11:19 am
Maintains
Neutral
Neutral
Goldman Sachs
Low
-2.2%
10/30
11:19 am
Maintains
Neutral
Neutral
Goldman Sachs
Low
-2.2%
12/17
05:54 pm
arqt
Low
Form 4 Arcutis Biotherapeutics, For: Dec 15 Filed by: Burnett Patrick
12/15
04:08 pm
arqt
Low
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
12/8
08:03 pm
arqt
Medium
Form 4 Arcutis Biotherapeutics, For: Dec 04 Filed by: Munshi Amit
12/8
08:01 pm
arqt
Medium
Form 3 Arcutis Biotherapeutics, For: Dec 04 Filed by: Munshi Amit
12/8
04:29 pm
arqt
Medium
Form 8-K Arcutis Biotherapeutics, For: Dec 03
Show more
Top News Gainers
3/19 Form 10-K Arcutis Biotherapeutics, For: Dec 31 33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
Top News Decliners
3/16 Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis -16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3